A prognostic model for advanced stage nonsmall cell lung cancer : Pooled analysis of North Central Cancer Treatment Group trials (pages 781–792)
Sumithra J. Mandrekar, Steven E. Schild, Shauna L. Hillman, Katie L. Allen, Randolph S. Marks, James A. Mailliard, James E. Krook, Andrew W. Maksymiuk, Kari Chansky, Karen Kelly, Alex A. Adjei and James R. Jett
Article first published online: 17 JUL 2006 | DOI: 10.1002/cncr.22049
In addition to the widely accepted prognostic factors of performance status, body mass index, and stage, pretreatment blood counts were significant prognostic factors for overall survival and time to progression in patients with advanced-stage nonsmall cell lung cancer. The authors developed a prediction equation based on the patients' own prognostic factors that may be used to evaluate the benefit of a treatment in Phase II trials by comparing the observed survival to the expected survival of a cohort in place of historic comparisons, which may have substantially different baseline patient characteristics. The usefulness of this work to clinical research and clinical practice is compelling in this population, in which advances in treatment have been slow, producing only modest improvements in survival.